SCHEMBL24601427

SCHEMBL24601427

CCOC(=O)C[C@H](C)c1cc2cc(NC(=O)c3ccccc3)ccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
TP53 P04637 3/20 0.53
POLB P06746 2/20 0.53
THRB P10828 2/20 0.53
HDAC1 Q13547 1/20 0.53
NPC1 O15118 6/20 0.48
RAB9A P51151 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.47
PDGFRB P09619 2/20 0.45
KDR P35968 2/20 0.45
CASP3 P42574 2/20 0.45
SENP8 Q96LD8 2/20 0.45
SENP7 Q9BQF6 2/20 0.45
SENP6 Q9GZR1 2/20 0.45
ALDH1A1 P00352 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24601429 0.87 HDAC1 (0.59) MAPTTP53HDAC1NPC1RAB9A
SCHEMBL1885247 0.79 HDAC1 (0.68) MAPTTP53POLBTHRBHDAC1
SCHEMBL24601431 0.76 ALDH1A1 (0.46) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL22718570 0.73 TP53 (0.45) MAPTTP53POLBTHRBHDAC1
SCHEMBL15697561 0.72 HDAC1 (0.74) MAPTHDAC1NPC1RAB9ASMN1; SMN2
SCHEMBL22718700 0.72 TP53 (0.54) MAPTTP53POLBTHRBHDAC1
SCHEMBL24601446 0.71 HDAC1 (0.66) MAPTTP53HDAC1NPC1RAB9A
SCHEMBL15697580 0.71 HDAC1 (0.82) MAPTTP53HDAC1NPC1RAB9A
SCHEMBL22718550 0.70 TP53 (0.55) MAPTTP53POLBTHRBHDAC1
SCHEMBL1886609 0.70 HDAC1 (1.00) HDAC1PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213052-A1 INHIBITORS OF RNA-BINDING PROTEINS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEROF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213052-A1 INHIBITORS OF RNA-BINDING PROTEINS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEROF HNRNPF, RBM3, RBM15 MAPT 1903/4885TP53 244/4885POLB 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.